Eli Lilly Migraine Drug Approved and Will Be Free to Patients
- Amgen, Teva already launched new drugs called CGRP-inhibitors
- Analysts predict Emgality will sell $701 million in 2022
This article is for subscribers only.
Eli Lilly & Co. got clearance from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
The Food and Drug Administration approved galcanezumab, a so called CGRP-inhibitor that will be marketed under the name Emgality, on Thursday. Indianapolis-based Lilly said it will offer the drug at no cost for a year to millions of patients with commercial insurance, a move that reflects increased scrutiny of high prescription costs in the U.S. and fierce competition in a hot treatment area.